Serotonin reuptake inhibitor antidepressants, including selective serotonin reuptake
inhibitors (SSRIs; ie, citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and …

Genetic factors can, to a certain extent, successfully predict the therapeutic effects,
metabolism, and adverse reactions of drugs. This research field, pharmacogenomics, is well …

Importance Evidence of the clinical benefit of pharmacogenetics-informed treatment (PIT)
with antidepressants is still limited. Especially for tricyclic antidepressants (TCAs) …

Background Major depressive disorder is a common, recurrent, disabling and costly disorder
that is often severe and/or chronic, and for which non-remission on guideline concordant first …

The aim of the study was to assess the clinical utility of currently available
pharmacogenomic (PGx) tools compared with treatment as usual (TAU), using a meta …

Realizing the promise of precision medicine in psychiatry is a laudable and beneficial
endeavor, since it should markedly reduce morbidity and mortality and, in effect, alleviate the …

Pharmacogenomic (PGx) testing may increase the probability of remission and response in
patients with major depressive disorder (MDD) undergoing pharmacotherapy. Given the …

Introduction: Clinically important depressive symptoms that occur in adults over age 60 are
often termed late-life depression (LLD). LLD poses challenges for treating clinicians in both …

The term severe mental illness (SMI) encompasses those psychiatric disorders exerting the
highest clinical burden and socio-economic impact on the affected individuals and their …

Abstract Background Traditionally tricyclic antidepressants (TCAs) have an important place
in treatment of major depressive disorder (MDD). Today, often other antidepressant …